Summary
Synopsis
Flumazenil, a 1,4-imidazobenzodiazepine, is a specific benzodiazepine antagonist which is indicated for use when the effect of a benzodiazepine must be quickly attenuated or terminated. Following intravenous administration, the onset of clinically apparent benzodiazepine antagonism usually occurs within 1 to 5 minutes. Although flumazenil has a short elimination half-life of about 1 hour, a single intravenous dose of up to 1mg is usually sufficient to attain and maintain for about 2 hours the desired level of consciousness after general anaesthesia or conscious to moderate sedation indued by benzodiazepines. After intoxication with high doses of benzodiazepines the initial single dose of flumazenil will require supplementing with repeated low intravenous doses or an infusion (0.1 mg/h) to maintain a state of wakefulness. Flumazenil is well tolerated, and since it reliably attenuates or reverses the central effects of benzodiazepines and is specific for these drugs, it facilitates diagnosis by eliminating benzodiazepine intoxication in patients in whom the cause of unconsciousness is unknown. While results of some studies suggested that flumazanil may have intrinsic benzodiazepine partial agonist or inverse agonist activity, this is unlikely to be clinically important with usual doses.
Thus, flumazenil is a very promising, effective, short acting benzodiazepine antagonist which is well tolerated by most patients. Undoubtedly, its full clinical potential has yet to be realised.
Pharmacodynamic Studies
Flumazenil is a benzodiazepine antagonist which inhibits the central effects of benzodiazepine agonists by competing with these drugs for the benzodiazepine receptor. In a variety of tests in mice, rats and cats, flumazenil 0.3 to 30 mg/kg intravenously, 0.5–10 mg/kg intraperitoneally, a total dose of 30 to 100mg orally and of 2.5µg by the intracerebroventricular route, has been shown to antagonise the central effects of benzodiazepine agonists (e.g. diazepam, triazolam, midazolam) and inverse agonists [e.g. dimethoxy-ethyl-carbomethoxy-β-carboline (DMCM)].
The inhibitory effect of flumazenil is specific for central benzodiazepine receptors. Following injection of 11C-flumazenil the pattern of distribution of radioactivity in human brain, as evidenced by the use of positron emission tomography, closely corresponded to the previously known distribution of benzodiazepine receptors in individual brain areas. These findings support the suggestion that in man, as in animals, flumazenil antagonises the central pharmacological effects of the benzodiazepines by interacting with these drugs at the central benzodiazepine receptor binding sites. The absence of change in plasma concentrations of diazepam or midazolam following administration of flumazenil at dosages that reversed the central effects of these benzodiazepines, indicated that flumazenil does not antagonise the actions of these drugs by altering their bioavailability. Numerous studies in healthy subjects have demonstrated that flumazenil 100 to 200mg orally or 2.5 to 20mg intravenously, antagonised the pharmacological effects (such as sedation, impaired cognitive and motor function, and anaesthesia) of diazepam, meclonazepam, flunitrazepam and midazolam when the benzodiazepine agonist and flumazenil were administered concomitantly or separately at various intervals.
While initial studies in animals failed to reveal any intrinsic pharmacological activity of flumazenil, subsequent studies in animals and in humans demonstrated both partial agonist and partial inverse agonist activity, albeit generally slight. In animals, partial agonist effects have been observed usually with high doses of flumazenil (30 to 50 mg/kg), while inverse agonist-like activity has been evident most often at lower doses. This latter activity has often been observed only under particular test and environmental conditions.
In humans however, evidence for intrinsic effects of flumazenil is less clear. Some reports of subjective mood changes have been interpreted as flumazenil-induced anxiety, but this is not convincing. In a detailed analysis of the effects of different doses of flumazenil in healthy subjects, it was reported that flumazenil 100mg orally produced benzodiazepine-like effects, and that the effects which were more pronounced at the lower dose of 30mg were unlike those of the benzodiazepines. In a small group of epileptic patients, flumazenil 2.5mg intravenously or 50mg orally, exhibited anticonvulsant activity in the EEG. Nevertheless, the intrinsic effects in humans are generally weak and seem unlikely to detract from its clinical use as a specific benzodiazepine antagonist.
Pharmacokinetic Properties
After oral administration of a single 200mg dose of flumazenil to healthy subjects a mean peak plasma concentration of 255 µg/L (range 143 to 439) was attained 41 minutes (mean) after ingestion. Similar plasma concentrations were attained 5 minutes after intravenous bolus administration of a single 20mg dose. Following oral administration flumazenil undergoes considerable first-pass metabolism in the liver, resulting in about 16% of the ingested dose reaching the systemic circulation in unchanged form.
In healthy subjects, positron tomography has indicated that distribution of radioactivity in the brain following injection of 11C-flumazenil corresponds closely to previously known distribution of benzodiazepine receptors. Average volume of distribution was about 1.1 L/kg following intravenous administration of flumazenil and was very similar after either 20 or 40mg doses.
Flumazenil is extensively metabolised in the liver, with only 0.12% (mean) excreted unchanged in the urine over a 12-hour period after intravenous injection. To date, 3 metabolites have been identified (N-desmethylflumazenil, N-desmethylflumazenil ‘acid’ and flumazenil ‘acid’). In healthy subjects total plasma clearance of flumazenil following single intravenous doses has been reported to range from 691 to 1198 ml/min (41 to 72 L/h) and elimination half-life was generally less than 1 hour.
Therapeutic Trials
The efficacy of flumazenil in reversing the central effects of benzodiazepines has been demonstrated in numerous, usually small, groups of patients. Much of the preliminary clinical experience has been during the recovery period following surgery in patients anaesthetised with midazolam or flunitrazepam, or sedated with midazolam for minor surgery or diagnostic procedures. Following general anaesthesia, flumazenil administered intravenously in individually titrated dosages of up to 1mg was clearly superior to placebo in reversing benzodiazepine-induced sedation, as assessed by sedation rating scores. Differences between treatment groups were significant 1 to 5 minutes after flumazenil or placebo administration, and remained so for 30 to 75 minutes. Mean duration of amnesia was also significantly shorter after flumazenil compared with placebo, although in some studies this difference was of doubtful clinical significance.
In patients sedated with midazolam or diazepam to a level where they were alseep but rousable on command, flumazenil at dosages of up to 1mg intravenously resulted in rapid recovery and shortening of amnesia. As expected, the clinical relevance of results with flumazenil in patients sedated with the short acting drug midazolam was less apparent than in patients sedated with the longer acting diazepam. In some instances the duration of a significant difference in alertness between flumazenil and placebo was only about 15 minutes in patients sedated with midazolam. In contrast, in subjects given diazepam, significant differences between flumazenil and placebo, as rated by sedation scales, persisted up to 120 minutes after flumazenil administration.
Intravenously administered flumazenil has been successfully used to reverse the central effects of high doses of benzodiazepines in small groups of patients who intentionally ingested overdoses, and in those in whom therapeutically administered benzodiazepines resulted in intoxication. In such patients flumazenil was usually administered at a dose of 0.2 to 0.5 mg/min until patients were fully awake or a total dose of several milligrams had been given. A return to consciousness generally occurred within 5 minutes in patients who were unconscious as a result of pure benzodiazepine overdose or intoxication. In patients in whom unconsciousness was due to ingestion of unknown drugs, administration of flumazenil facilitated diagnosis by eliminating the effects of any benzodiazepines ingested. The duration of effect of the initially effective dose of flumazenil generally varied from 1 to 2 hours to 3 to 5 hours, although in some patients, sedation did not reappear after its reversal by flumazenil.
Side Effects
Usual therapeutic doses of flumazenil have been very well tolerated by most patients. Only nausea and/or vomiting occurred in more than 1% of patients who received flumazenil for the reversal of benzodiazepine-induced sedation or general anaesthesia. In double-blind trials in anaesthesiology, side effects were observed in 21% of patients receiving flumazenil and 10% given placebo. However, the higher incidence of nausea and vomiting experienced by anaesthetised patients compared with other groups treated with flumazenil suggests that such effects may have been due in part to ancillary drug therapy or to the surgical procedure. In patients treated for benzodiazepine intoxication, the most frequent event was agitation (6.5%), followed by discomfort (unspecified), tearfulness, anxiety and a sensation of coldness. These usually mild effects have generally not been regarded as benzodiazepine withdrawal symptoms. Careful analysis of reported side effects indicated possible withdrawal effects precipitated by flumazenil have occurred in fewer than 1% of patients.
Dosage and Administration
The dosage of flumazenil should be titrated individually to obtain the desired level of consciousness. Generally, doses of 0.3 to 0.6mg administered intravenously have been adequate to reduce the degree of sedation to the required extent in patients sedated or anaesthetised with benzodiazepines for carrying out surgery, while doses of 0.5 to 1mg are usually sufficient to completely abolish the effect of a therapeutic dose of a benzodiazepine in other settings. In patients who are unconscious due to ingestion of an overdose of drugs that have not been positively identified, failure to respond to intravenous doses of 5mg flumazenil may indicate the involvement of intoxicants other than benzodiazepines or the presence of functional or organic disorders.
Similar content being viewed by others
References
Abernethy DR, Arendt RM, Lauven PM, Greenblatt DJ. Determination of Ro 15-1788, a benzodiazepine antagonist, in human plasma by gas-liquid chromatography with nitrogen-phosphorus detection. Pharmacology 26: 285–289, 1983
Alon E, Baitella L, Hossli G. Double-blind study of the reversal of midazolam-supplemented general anaesthesia with Ro 15-1788. British Journal of Anaesthesia 59: 455–458, 1987
Amrein R, Leishman B, Bentzinger C, Roncari G. Flumazenil in benzodiazepine antagonism: actions and clinical use in intoxications and anaesthesiology. Medical Toxicology 2: 411–429, 1987
Bichard AR, Little HJ. Ro 15-1788 antagonizes the protective effects of flurazepam in the high pressure neurological syndrome. British Journal of Pharmacology 76 (Suppl. June) 240P, 1982
Bichard AR, Little HJ. Differential effects of the benzodiazepine antagonist Ro 15-1788 on the ‘general anaesthetic’ actions of the benzodiazepines. British Journal of Anaesthesia 55: 912P, 1983
Bonetti EP, Pieri L, Cumin R, Schaffner M, Pieri M, et al. Benzodiazepine antagonist Ro 15-1788: neurological and behavioural effects. Psychopharmacology 78: 8, 1982
Braestrup C, Nielsen M, Honoré T, Jensen LH, Petersen EN. Benzodiazepine receptor ligands with positive and negative efficacy. Neuropharmacology 22: 1451–1457, 1983
Braestrup C, Schmiechen R, Neef G, Nielsen M, Petersen EN. Interaction of convulsive ligands with benzodiazepine receptors. Science 216: 1241–1243, 1982
Chiolero R, Ravussin P, Chassot P-G, Neff R, Freeman J. Ro 15-1788 for rapid recovery after craniotomy. Anesthesiology 65: Abstract A466, 1986
Cumin R, Bonetti EP, Scherschlicht R, Haefely WE. Use of the specific benzodiazepine antagonist Ro 15-1788 in studies of physiological dependence on benzodiazepines. Experientia 38: 833, 1982
Dantzer R, Perio A. Behavioural evidence for partial agonist properties of Ro 15-1788, a benzodiazepine receptor antagonist. European Journal of Pharmacology 81: 655–658, 1982
Darragh A, Lambe R, Brick I, Wilson Downie W. Reversal of benzodiazepine-induced sedation by intravenous Ro 15-1788. Lancet 2: 1042, 1981a
Darragh A, Lambe R, Kenny M, Brick I, Taafe W, et al. Ro 15-1788 antagonises the central effects of diazepam in man without altering diazepam bioavailability. British Journal of Clinical Pharmacology 14: 677–682, 1982
Darragh A, Lambe R, O’Boyle C, Kenny M, Brick I. Absence of central effects in man of the benzodiazepine antagonist Ro 15-1788. Psychopharmacology 80: 192–195, 1983
Darragh A, Lambe R, Scully M, Brick I. Investigation in man of the efficacy of a benzodiazepine antagonist, Ro 15-1788. Lancet 2: 8–10, 1981
Darragh A, O’Boyle C, Lambe R, Brick I. Antagonism of the central effects of diazepam in man by Ro 15-1788 a novel benzodiazepine antagonist. Irish Journal of Medical Science 151: 90, 1982a
De Vry J, Slangen JL. The Ro 15-1788 cue: evidence for benzodiazepine agonist and inverse agonist properties. European Journal of Pharmacology 119: 193–197, 1985
Doenicke A. Modern trends in the investigation of new hypnotics in anaesthesia. In Hindmarch et al. (Eds) Psychopharmacology (Suppl. 1), pp. 119–132, 1984
Duka TH, Ackenheil M, Dorow R, Noderer J, Welter D, Doenicke A. Precipitated withdrawal by the benzodiazepine antagonist Ro 15-1788 with noradrenaline plasma levels. Abstract. Presented at 14th Collegium Internationale Neuro-Psychopharmacologicum Congress, Firenze, June, 1984
Ehrin E, Johnström P, Stone-Elander S, Nilsson JLG, Persson A, et al. Preparation of carbon-II labelled Ro 15-1788, a selective benzodiazepine receptor antagonist, and preliminary positron emission tomography studies. In Dahlbom & Nilsson (Eds) Medicinal chemistry 2, pp. 284–286, Swed. Pharm. Press, Stockholm, 1985
Emrich HM, Lund R. Effect of the benzodiazepine antagonist Ro 15-1788 on sleep after sleep withdrawal. Pharmacopsychiatry 18: 171–173, 1985
Emrich HM, Sonderegger P, Mai N. Action of the benzodiazepine antagonist Ro 15-1788 in humans after sleep withdrawal. Neuroscience Utters 47: 369–373, 1984
File SE, Dingemanse J, Friedman HL, Greenblatt DJ. Chronic treatment with Ro 15-1788 distinguishes between its benzodiazepine antagonist, agonist and inverse agonist properties. Psychopharmacology 89: 113–117, 1986
File SE, Pellow S. The anxiogenic action of Ro 15-1788 is reversed by chronic, but not by acute treatment with chlordiazepoxide. Brain Research 310: 154–156, 1984
File SE, Pellow S. Intrinsic actions of the benzodiazepine receptor antagonist Ro 15-1788. Psychopharmacology 88: 1–11, 1986
File SE, Pellow S. The benzodiazepine receptor antagonist Ro 15-1788 has anxiogenic activity in four animal tests of anxiety. British Journal of Pharmacology 84 (Suppl. March): 103P, 1985
Forster A, Juge O, Louis M, Nahory A. Effects of a specific benzodiazepine antagonist (Ro 15-1788) on cerebral blood flow. Anaesthesia and Analgesia 66: 309–313, 1987
Gaillard JM. Effects of a benzodiazepine antagonist on sleep and making EEG. Electroencephalography and Clinical Neurophysiology 61: 55P, 1985
Gaillard JM, Blois R. Effect of the benzodiazepine antagonist Ro 15-1788 on flunitrazepam-induced sleep changes. British Journal of Clinical Pharmacology 15: 529–536, 1983
Gee KW, Yamamura H. A novel pyrazploquinoline that interacts with brain benzodiazepine receptors: characterisation of some in vitro and in vivo properties of CGS 9896. Life Sciences 30: 2245–2252, 1982
Geller E, Chernilas J, Halpern P, Niv D, Miller HI. Hemodynamics following reversal of benzodiazepine sedation with Ro 15-1788 in cardiac patients. Anesthesiology 65(3A): A49, 1986a
Geller E, Niv D, Matzkin C, Braf Z. The reversal of midazolam sedation by Ro 15-1788 in patients undergoing surgery under epidural anesthesia. Anaesthesist 34 (Suppl.): 139, 1985
Geller E, Niv D, Matzkin C, Silbiger A, Nevo I, et al. The antagonism of midazolam sedation by Ro 15-1788 in 50 postoperative patients. Abstract A369. Anesthesiology 63: 3A, 1985b
Geller E, Niv D, Rudick V, Vidne B. The use of Ro 15-1788, a benzodiazepine antagonist, in the diagnosis and treatment of benzodiazepine overdose. Abstract 135. Anesthesiology 61(3A), 1984
Geller E, Niv D, Silbiger A, Halpern P, Leykin Y, et al. Ro 15-1788 a benzodiazepine antagonist in the treatment of 34 intoxicated patients. Abstract 157. Anesthesiology 63(3A), 1985a
Geller E, Silbiger A, Niv D, Nevo Y, Beihassen B. The reversal of benzodiazepam sedation with Ro 15-1788 in brief procedures. Anesthesiology 65(3A): A357, 1986
Geller E, Weinbrum A, Halpern P, Nevo Y, Rudick V. Flumazenil, the specific benzodiazepine receptor antagonist (Ro 15-1788) affects recovery from halothane anaesthesia. Anesthesiology 67(3A): A422, 1987
Gerhardt S, Liebman JM. Self-regulation of ICSS duration: effects of anxiogenic substances, benzodiazepine antagonists and anti-depressants. Pharmacology Biochemistry and Behaviour 22: 71–76, 1985
Grecksch G, de Carvalho LP, Venault P, Chapouthier G, Rossier J. Convulsions induced by submaximal dose of pentylenetetrazole in mice are antagonised by the benzodiazepine antagonist Ro 15-1788. Life Sciences 32: 2579–2584, 1983
Havoundjian H, Reed GF, Paul SM, Skolnick P. Protection against the lethal effects of pentobarbital in mice by a benzodiazepine receptor inverse agonist, 6,7-dimethoxy-4-ethyl-3-carbome-thoxy-β-carboline. Journal of Clinical Investigation 79: 473–477, 1987
Higgitt A, Lader M, Fonagy P. The effects of the benzodiazepine antagonist Ro 15-1788 on psychophysiological performance and subjective measures in normal subjects. Psychopharmacology 89: 395–403, 1986
Hillman GR. The neuropharmacology of schistosomes. Pharmacology and Therapeutics 22: 103–115, 1983
Hofer P, Scollo-Lavizzari G. Benzodiazepine antagonist Ro 15-1788 in self-poisoning. Archives of Internal Medicine 145: 663, 1985
Hofer P, Scollo-Lavizzari G. Diagnosis and treatment of drug overdosage with Ro 15-1788, a specific benzodiazepine antagonist. Paper presented at the 4th World Congress on Intensive and Critical Care Medicine, Jerusalem, June 23–28, Abstract 213, 1985a
Hünkeler W, Möhler M, Pieri L, Polc P, Bonetti EP, et al. Selective antagonists of benzodiazepines. Nature (London) 290: 514–516, 1981
Jensen S, Kirkegaard L, Andersen BN. Benzodiazepine antagonist Ro 15-1788: randomised clinical investigation of Ro 15-1788 in reversing the central effects of flunitrazepam. Abstract 162. Acta Anaesthesiologica Scandinavica 29(Suppl. 80): 89, 1985
Jensen S, Kirkegaard L, Andersen BN. Randomised clinical investigation of Ro 15-1788, a benzodiazepine antagonist, in reversing the central effects of flunitrazepam. European Journal of Anaesthesiology 4: 113–118, 1987
Kaijima M, La Salle G, Rossier J. The partial benzodiazepine agonist properties of Ro 15-1788 in pentylenetetrazole-induced seizures in cats. European Journal of Pharmacology 93: 113–115, 1983
Kirkegaard L, Knudsen L, Jensen S, Kruse A. Benzodiazepine antagonist Ro 15-1788. Anaesthesia 41: 1184–1188, 1986
Kleinberger G, Grimm G, Laggner A, Druml W, Lenz K, et al. Weaning patients from mechanical ventilation by benzodiazepine antagonist Ro 15-1788. Lancet 2: 268, 1985
Klotz U, Duka Th, Dorow R, Doenicke A. Flunitrazepam and lormetazepam do not affect the pharmacokinetics of the benzodiazepine antagonist Ro 15-1788. British Journal of Clinical Pharmacology 19: 95–98, 1985a
Klotz U, Kanto J. Pharmacokinetics and clinical use of flumazenil (Ro 15-1788). Clinical Pharmacokinetics 14: 1–12, 1988
Klotz U, Ziegler G, Ludwig L, Reimann IW. Pharmacodynamic interaction between midazolam and a specific benzodiazepine antagonist in humans. Journal of Clinical Pharmacology 25: 400–406, 1985
Klotz U, Ziegler G, Reimann IW. Pharmacokinetics of the selective benzodiazepine antagonist Ro 15-1788 in man. European Journal of Clinical Pharmacology 27: 115–117, 1984
Klotz U, Ziegler G, Rosenkranz B, Mikus G. Does the benzodiazepine antagonist Ro 15-1788 antagonise the action of ethanol? British Journal of Clinical Pharmacology 22: 513–520, 1986
Kunchandy J, Kulkami SK. Apparent pA2 estimation of benzodiazepine receptor antagonists. Methodology and Findings in Experimental Clinical Pharmacology 8: 553–555, 1986
Lambe RF, Brick I, Darragh A, O’Boyle CO. Pharmacological antagonism of the cognitive psychomotor and amnesic effects of benzodiazepines in man by oral and intravenous flumazenil. Collegium Internationale Neuro-Psychopharmacologicum 14th CINP Congress, Abstract P-729 Fidia Research Biomedical Information, 1984
Laurian S, Gaillard JM, Le PK, Schöpf J. Effects of a benzodiazepine antagonist on the diazepam-induced electrical brain activity modifications. Neuropsychobiology 11: 55–58, 1984
Lauven PM, Schwilden H, Stoeckel H, Greenblatt DJ. The effects of a benzodiazepine antagonist (Ro 15-1788) in the presence of stable concentrations of midazolam. Anaesthesiology 63: 61–64, 1985
Leykin Y, Silbiger A, Sorkine P, Niv D, Geller E. Analysis of ICU management of acute poisoning: a 3 year study. Paper presented at the 4th World Congress on Intensive and Critical Care Medicine, Jerusalem, June 23–28, Abstract 208, 1985
Lheureux P, Askenasi R. Benzodiazepine antagonist Ro 15-1788 in self-poisoning. Archives of Internal Medicine 146: 1241, 1986
Lheureux P, Askenasi R. Specific treatment and quick diagnosis of benzodiazepine and alcohol overdoses in the emergency department. Abstract 29. Annals of Emergency Medicine 16: 485, 1987
Lingjaerde O. Effects of the benzodiazepine receptor ligands midazolam, Ro 15-1788 and Ro 5-4864, alone and in combinations, on platelet serotonin uptake. Pharmacopsychiatry 19: 15–18, 1986
Louis M, Forster A, Suter PM, Gemperle M. Clinical and hemodynamic effects of a specific benzodiazepine antagonist (Ro 15-1788) after open heart surgery. Anesthesiology 61(3A): A61, 1984
Lupolover Y, Safran AB, Desangles D, de Weisse C, Meyer JJ, et al. Evaluation of visual function in healthy subjects after administration of Ro 15-1788. European Journal of Clinical Pharmacology 27: 505–507, 1984
Marano F, Santa-Maria A, Fries W. Effects of diazepam on mitosis and basal body duplication of synchronously dividing flagellate cells. Journal of Submicroscopic Cytology 16: 125, 1984
Martinez-Aguirre E, Navarro T. Ro 15-1788, a highly specific benzodiazepine antagonist: preliminary clinical experience. In Boulton T (Ed.) 6th European congress of anaesthesiology, London, Sept 8–15, 1982, Abstract 810. Academic Press, London, 1982
Miller LG, Greenblatt DJ, Paul SM, Shader RI. Benzodiazepine receptor occupancy in vivo: correlation with brain concentrations and pharmacodynamic actions. Journal of Pharmacology and Experimental Therapeutics 240: 516–522, 1987
Mindus P, Ehrin E, Ericsson L, Farde L, Hedström CG, et al. Central benzodiazepine receptor binding studied with 11C labelled Ro 15-1788 and positron emission tomography. Pharmacopsychiatry 19: 2–3, 1986
Mönier H, Burkard WP, Keller HH, Richards JG, Haefely W. Benzodiazepine antagonist Ro 15-1788: binding characteristics and interaction with drug-induced changes in dopamine turnover and cerebellar GMP levels. Journal of Neurochemistry 37: 714, 1981
Monier H, Richards JG. Agonist and antagonist benzodiazepine receptor interaction in vitro. Nature 294: 763–765, 1981
Murphy SM, Owen RT, Tyrer PJ. Withdrawal symptoms after six weeks’ treatment with diazepam. Lancet 2: 1389, 1984
Najim RA, Al-Essa LY, Al-Jibouri LM. Benzodiazepine-induced hyperglycemia. Med. Sci. Research 15: 95–96, 1987
Nutt DJ, Cowen PJ, Little HJ. Unusual interactions of benzodiazepine receptor antagonists. Nature 295: 436, 1981
O’Boyle C, Lambe R, Darragh A, Taaffe W, Brick I, et al. Ro 15-1788 antagonises the effects of diazepam in man without affecting its bioavailability. British Journal of Anaesthesia 55: 349–355, 1983
Olsen RW. Drug interactions at the GABA receptor ionophore complex. Annual Review of Pharmacology and Toxicology 22: 245–277, 1982
O’Sullivan GF, Wade DN. Flumazenil in the management of acute drug overdosage with benzodiazepines and other agents. Clinical Pharmacology and Therapeutics 42: 254, 1987
Pellow S, File SE, Herberg LJ. Intracranial self-stimulation distinguishes between two benzodiazepine antagonists. Neuroscience Letters 47: 173–177, 1984
Persson A, Ehrin E, Eriksson L, Farde L, Hedstrom C-G, et al. Imaging of [11C]-labelled Ro 15-1788 binding to benzodiazepine receptors in the human brain by positron emission tomography. Journal of Psychiatric Research 19: 609–622, 1985
Pieri L. Preclinical pharmacology of midazolam. British Journal of Clinical Pharmacology 16: 17S–27S, 1983
Polc P, Bonetti EP, Schaffner R, Haefely W. A three-state model of the benzodiazepine receptor explains the interactions between the benzodiazepine antagonist Ro 15-1788, benzodiazepine tranquilizers, β-carbolines and phenobarbitone. Naunyn-Schmiedeberg’s Archives of Pharmacology 321: 260–264, 1982
Polc P, Laurent J-P, Scherschlicht R, Haefely W. Electrophysiological studies on the specific benzodiazepine antagonist Ro 15-1788. Archives of Pharmacology 316: 317, 1981
Richards JG, Möhler H. Benzodiazepine receptors. Neuropharmacology 23: 233–242, 1984
Ricou B, Forster A, Bruckner A, Chastonay P, Gemperle M. Clinical evaluation of a specific benzodiazepine antagonist (Ro 15-1788). British Journal of Anaesthesiology 58: 1005–1011, 1986
Roncari G, Ziegler WH, Guentert TW. Pharmacokinetics of the new benzodiazepine antagonist Ro 15-1788 in man following intravenous and oral administration. British Journal of Clinical Pharmacology 22: 421–428, 1986
Ruhland M, Fuchs AM. Lack of antagonism by Ro 15-1788 on timelotem (KC 7507) — a benzodiazepine with antipsychotic and anxiolytic properties. Pharmacopsychiatry 19: 216–217, 1986
Samson Y, Hantraye P, Baron JC, Soussaline F, Comar D, et al. Kinetics and displacement of [11C] Ro 15-1788, a benzodiazepine antagonist, studied in human brain in vivo by positron tomography. European Journal of Pharmacology 110: 247–251, 1985
Sanger DJ. Investigation of the actions of the benzodiazepine antagonists Ro 15-1788 and CGS 8216 using the schedule-controlled behaviour of rats. Pharmacology Biochemistry and Behaviour 25: 537–541, 1986
Schöpf J, Laurian S, Le PK, Gaillard JM. Intrinsic activity of the benzodiazepine antagonist Ro 15-1788 in man: an electro-physiological investigation. Pharmacopsychiatry 17: 79–83, 1984
Scollo-Lavizzari G. First clinical investigation of the benzodiazepine antagonist Ro 15-1788 in comatose patients. European Neurology 22: 7–11, 1983
Scollo-Lavizzari G. The anticonvulsant effect of the benzodiazepine antagonist, Ro 15-1788: an EEG study in 4 cases. European Neurology 23: 1–6, 1984
Scollo-Lavizzari G, Matthis H. Benzodiazepine antagonist (Ro 15-1788) in ethanol intoxication: a pilot study. European Neurology 24: 352–354, 1985
Scollo-Lavizzari G, Steinmann E. Reversal of hepatic coma by benzodiazepine antagonist Ro 15-1788. Lancet 1: 1324, 1985
Velucci SV, Webster RA. Is Ro 15-1788 a partial agonist at benzodiazepine receptors? European Journal of Pharmacology 90: 263–268, 1983
Wagner JA, Katz RJ. Anxiogenic action of benzodiazepine antagonists Ro 15-1788 and CGS 8216 in the rat. Neuroscience Letters 48: 317–320, 1984
Wolff J, Carl P, Clausen TG, Mikkelsen BO. Ro 15-1788 for postoperative recovery: a randomised clinical trial in patients undergoing minor surgical procedures under midazolam anaesthesia. Anaesthesia 41: 1001–1006, 1986
Zambotti F, Zonta N, Tammiso R, Ferrario P, Hafner B, et al. Reversal of the effect of centrally administered diazepam on morphine antinociception by specific (Ro 15-1788 and Ro 15-3505) and non-specific (bicuculline and caffeine) benzodiazepine antagonists. Naunyn-Schmiedeberg’s Archives of Pharmacology 333: 43–46, 1986
Zell M, Timm U. Highly sensitive assay of a benzodiazepine antagonist in plasma by capillary gas chromatography with nitrogen-selective detection. Journal of Chromatography 382: 175–188, 1986
Ziegler G, Ludwig L, Fritz G. Reversal of slow-wave sleep by benzodiazepine antagonist Ro 15-1788. Lancet 2: 510, 1985
Author information
Authors and Affiliations
Additional information
Various sections of the manuscript reviewed by: D.R. Abernethy, Division of Clinical Pharmacology, Brown University, Roger Williams General Hospital, Providence, Rhode Island, USA; E. Alon, Institute of Anaesthesiology, University Hospitalof Zurich, Zurich, Switzerland; G Braestrup, Novo Industrias, Bagsvaerd, Denmark; A. Darragh, Institute of Clinical Pharmacology, Dublin, Ireland; S.E. File, MRC Neuropharmacology Research Group, The School of Pharmacy, University of London, London, England; E. Geller, Department of Anesthesia, Iehilor Hospital, Tel Aviv, Israel; D.J. Greenblatt, Division of Clinical Pharmacology, Tufts-New England Medical Center, Boston, Massachusetts, USA; A Higgitt, The Bethlem Royal Hospital and the Maudsley Hospital, London, England; L. Kirkegaard, Department of Anaesthesiology, Aalborg Sygehus, Aalborg, Denmark; U. Klotz, Institute of Psychomatic Research, Stuttgart, Germany; P. Mindus, Department of Neurosurgery, The Karolinska Hospital, Stockholm, Sweden; C. O’Boyle, Health Care and Psychosomatic Unit, Garden Hill, Dublin, Ireland; L.F. Prescott, University Department of Clinical Pharmacology, The Royal Infirmary, Edinburgh, Scotland; B. Ricou, Department of Anesthesiology, University Hospital of Geneva, Geneva, Switzerland; C. Scollo-Lavizzâri, University Neurological Clinical, Kantonsspital, Basle, Switzerland; J.A. Vale, West Midlands Poisons Unit, Dudley Road Hospital, Birmingham, England; J. Wolff, Department of Anaesthesia, Bispebjerg Hospital, Copenhagen, Denmark.
Rights and permissions
About this article
Cite this article
Brogden, R.N., Goa, K.L. Flumazenil. Drugs 35, 448–467 (1988). https://doi.org/10.2165/00003495-198835040-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198835040-00004